Closed to Accrual
IMPAACT 2001, a PK study of rifapentine and isoniazid in pregnant and postpartum women, is now closed to accrual.
Abstracts Presented
The IMPAACT Network presented 8 abstracts as posters and oral presentations at AIDS 2018. Additional abstracts were presented at the HIV Pediatrics Workshop. Presentations will be posted soon.
Resources
IMPAACT has partnered with the World Health Organization (WHO) and other organizations to develop a toolkit for the research and development of pediatric antiretroviral drugs and formulations.
See Toolkit
Meetings
Thank you to everyone who attended the 2018 IMPAACT Network Annual Meeting! Photos and some presentations are now available.
See more
Our mission
Our mission is to significantly decrease incident HIV and HIV-associated infections and to decrease mortality and morbidity due to HIV and HIV-associated infections and co-morbidities among infants, children, adolescents and pregnant/postpartum women.
This document highlights major steps in protocol implementation and gives a quick look at accrual for each study. It is updated monthly.
Proposals for new IMPAACT studies may be submitted by internal or external investigators in the form of a three-page study "capsule" any time.
Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.
